The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports

Strong Early Launch Metrics for Biotech's Skin Disease Drug

Research Report
  ()
Oren Livnat of H.C. Wainwright & Co. sees over 240% upside potential for Verrica Pharmaceuticals based on the early commercial success of its recently launched skin disease treatment.
Tags:  Biotechnology / Pharmaceuticals

Showing Results: 51 to 51 of 51 Prev